Royalty Pharma plc Website

Royalty Pharma plc

NasdaqGS-RPRX

Basic

  • Market Cap

    $12.97B

  • EV

    $21.6B

  • Shares Out

    452.11M

  • Revenue

    $2,238.56M

  • Employees

    —

Margins

  • Gross

    54.19%

  • EBITDA

    63.61%

  • Operating

    41.96%

  • Pre-Tax

    53.01%

  • Net

    35.69%

  • FCF

    116.98%

Returns (5Yr Avg)

  • ROA

    4.65%

  • ROTA

    8.13%

  • ROE

    8.1%

  • ROCE

    8.92%

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $45.38

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    $872M

  • Net Debt

    $5,267.38M

  • Debt/Equity

    0.62

  • EBIT/Interest

    5.09

Growth (CAGR)

  • Rev 3Yr

    0.66%

  • Rev 5Yr

    5.58%

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    13.69%

  • Dil EPS 5Yr

    -41.67%

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    11.36%

  • EBITDA Fwd 2Yr

    -1.37%

  • EPS Fwd 2Yr

    -0.17%

  • EPS LT Growth Est

    4.45%

Dividends

  • Yield

    —

  • Payout

    45.46%

  • DPS

    $0.81

  • DPS Growth 3Yr

    19.89%

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    10.45%

Select a metric from the list below to chart it

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Total Revenues

1,814.3

2,122.4

2,289.5

2,237.2

2,354.6

2,238.6

Total Revenues % Chg.

—

1.1%

17%

7.9%

-2.3%

5.2%

-5.1%

Cost of Goods Sold, Total

-1,019.3

230.8

452.8

904.2

560.7

1,025.5

Gross Profit

2,833.6

1,891.5

1,836.6

1,333

1,793.9

1,213.1

Selling General & Admin Expenses, Total

103.4

181.7

182.8

227.3

249.7

221.7

R&D Expenses

83

26.3

200.1

177.1

52

52

Amortization of Goodwill and Intangible Assets

23.9

23.1

23

5.7

—

—

Other Operating Expenses, Total

210.4

231.1

405.9

410.1

301.7

273.7

Operating Income

2,623.2

1,660.5

1,430.7

922.9

1,492.2

939.4

Interest Expense, Total

-341.2

-168

-166.1

-188

-187.2

-184.5

Interest And Investment Income

22.3

28.4

53.5

78.3

72.3

63

Net Interest Expenses

-318.9

-139.6

-112.6

-109.6

-114.9

-121.5

Income (Loss) On Equity Invest.

-32.5

44.5

-19.5

-9

28.9

-19.9

Other Non Operating Income (Expenses)

33.9

-33.5

-27.2

81.9

-24

-32

EBT, Excl. Unusual Items

2,305.7

1,531.8

1,271.4

886.1

1,382.1

766.1

Gain (Loss) On Sale Of Investments

155.7

265.7

-30.2

-40.3

318

420.6

Gain (Loss) On Sale Of Assets

—

—

—

—

—

—

—

Asset Writedown

—

—

—

-65.1

—

-615.8

—

—

Other Unusual Items

—

—

—

-30.5

—

—

—

—

EBT, Incl. Unusual Items

2,461.4

1,702

1,241.2

230.1

1,700.1

1,186.7

Earnings From Continuing Operations

2,461.4

1,702

1,241.2

230.1

1,700.1

1,186.7

Minority Interest

-112.9

-726.9

-621.5

-187.2

-565.3

-387.9

Net Income

2,348.5

975

619.7

42.8

1,134.8

798.9

Preferred Dividend and Other Adjustments

—

—

—

479.8

—

—

—

—

Net Income to Common Incl Extra Items

2,348.5

495.2

619.7

42.8

1,134.8

798.9

Net Income to Common Excl. Extra Items

2,348.5

495.2

619.7

42.8

1,134.8

798.9

Total Shares Outstanding

—

—

388.1

433

443.2

446.7

451

Weighted Avg. Shares Outstanding

—

—

375.4

414.8

438

447.6

448.4

Weighted Avg. Shares Outstanding Dil

—

—

375.5

414.8

438

602.9

600.5

EPS

—

—

1.3

1.5

0.1

2.5

1.8

EPS Diluted

—

—

1.3

1.5

0.1

2.5

1.8

EBITDA

2,647.1

1,683.5

1,453.7

928.6

1,497.8

—